PLANET-TRACKER
26.6.2024 17:01:35 CEST | Business Wire | Press release
Access to Nutrition Initiative (ATNI) and Planet Tracker, in association with The Global Alliance for Improved Nutrition, have published a seminal Materiality of Nutrition Report. The first collaboration between ATNI and Planet Tracker sets the scene for a new conversation – how can healthier foods drive healthy profits, people and planet?
The report compares the healthiness of food product portfolios from 20 of the largest global food manufacturers with their profits and market valuations. The findings reveal a link between healthier food product portfolios and higher profitability but this is obscured by poor company disclosures.
Key Findings
NB: The sample size is only 20 companies. Neither ATNI nor Planet Tracker wish to suggest this report is more than a discussion paper to stimulate further debate.
Health & Profitability: Analysis shows that companies with broader, healthier food portfolios have higher average profit margins (15.2%) compared to those with unhealthy portfolios (13.4%). However, a subset specializing in unhealthy products, like soft drinks, shows even higher margins (16.7%), highlighting the complexity of the market.
Health Star Rating (HSR) and EBIT: Understanding the relationship between HSR and EBIT is key to drive investments towards health and wealth. Our findings suggest there is not a strong negative association, in the companies assessed, between HSR and EBIT. What’s more, our results suggest there are positive associations between HSR and EBIT among smaller companies with broad portfolios.
Investment Opportunities: In addition to the obvious benefits to society, investors would benefit from a switch to healthier foods. In a scenario where companies with unhealthy portfolios switch to healthier products and achieved similar margins, profits would also rise by nearly USD 350 million and valuations by USD 60 billion.
Investment risks: Most companies fail to provide sufficient information, making it difficult for investors to assess the impact of nutrition on their valuations. This lack of transparency is a missed opportunity for companies and a risk for investors, particularly with potential regulations on the horizon.
Social & Economic Impact: Unhealthy food products reduce productivity, increase costs for employers, and impose a significant burden on society, potentially reducing GDP by 3.3% and life expectancy by three years by 2050.
Policy & Regulation: Effective policy actions in various countries signal rising pressure for broader regulation, posing risks (and opportunities) or companies relying on unhealthy products and the financial institutions that support them.
Greg S Garrett, Executive Director, Access to Nutrition Initiative,
“This report is part of a small but critical and growing body of evidence showing that food companies should improve the healthiness of their portfolios and disclosures. By not doing so, they increase their own risk and miss the opportunity to improve societal outcomes.”
Peter Elwin, Head of the Food and Land Use programme at Planet Tracker,
“Unhealthy food products are costing society and employers, but the issue is being overlooked by financial institutions. Regulation presents an increasing threat to companies profiting from producing unhealthy foods, but poor disclosure is hiding the risks. Our analysis shows that there could be investment opportunities associated with producing healthy food so there’s an incentive for investors to ask for change.”
Read the report here.
About ATNI
ATNI is a global non-profit founded in 2013 that exists for the sole purpose of transforming markets for nutrition. ATNI believes the private sector has an important role to play in fighting malnutrition. ATNI’s mission is to improve (financial) market performance by challenging key actors in the food system – notably industry and investors – to accelerate access to affordable, sustainable, and nutritious food for all, especially for society’s most vulnerable. ATNI does this through the development and publication of accountability tools and strategies in close collaboration with industry, investors, policymakers, consumers organizations and other nutrition stakeholders.
About Planet Tracker
Planet Tracker is an award-winning non-profit financial think tank aligning capital markets with planetary boundaries. Created with the vision of a financial system that is fully aligned with a net-zero, resilient, nature positive and just economy well before 2050, Planet Tracker generates break-through analytics that reveal both the role of capital markets in the degradation of our ecosystem and show the opportunities of transitioning to a zero-carbon, nature positive economy.
About GAIN
The Global Alliance for Improved Nutrition (GAIN) is a Swiss-based foundation launched at the United Nations in 2002 to tackle the human suffering caused by malnutrition. Working with governments, businesses and civil society, GAIN aims to transform food systems so that they deliver more nutritious foods for all people, especially the most vulnerable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626413872/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
